

## Mozambique

### Support for Vaccine: Measles Rubella This Decision Letter sets out the Programme Terms of a Programme.

<b>1. Country:</b>	Mozambique						
<b>2. Vaccine grant number:</b>	19-MOZ-18e-X, 20-MOZ-18e-X						
<b>3. Date of Decision Letter:</b>	30 September 2019						
<b>4. Date of the Partnership Framework Agreement:</b>	06 December 2013						
<b>5. Programme title:</b>	New Vaccine Support (NVS), Measles Rubella, 2D Routine						
<b>6. Vaccine type:</b>	Measles Rubella						
<b>7. Requested product presentation and formulation of vaccine:</b>	Measles Rubella, 10 dose(s) per vial, LYOPHILISED						
<b>8. Programme Duration:<sup>1</sup></b>	2019-2020						
<b>9. Programme Budget (indicative):<sup>2</sup></b>	(subject to the terms of the Partnership Framework Agreement, if applicable)						
	2019	2020	2021	2022	2023	2024	Total <sup>2</sup>
Programme Budget (US\$)	566,000	478,000	-	-	-	-	1,044,000
<b>10. Vaccine introduction grant</b>	<b>Not applicable</b>						
<b>11. Product switch grant</b>	Not applicable						
<b>12. Indicative Annual Amounts:<sup>3</sup></b>	(subject to the terms of the Partnership Framework Agreement, if applicable)						
<b>Type of supplies to be purchased with Gavi funds</b>	<b>2019</b>		<b>2020</b>				
Number of vaccine doses			705,800				
Annual Amounts (US\$)	566,000		478,000				

<sup>1</sup> This is the entire duration of the programme.

<sup>2</sup> This is the total amount endorsed by Gavi for the entire duration of the programme.

<sup>3</sup> This is the amount that Gavi has approved.

<b>13. Procurement agency:</b>	UNICEF. The Country shall release its co-financing payments each year to UNICEF.														
<b>14. Self-procurement:</b>	Not applicable														
<b>15. Co-financing obligations:</b>	<p>According to the co-financing policy, the Country falls within the group: <span style="float: right;">Initial self-financing</span></p> <p>The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.</p> <table border="1"> <thead> <tr> <th>Type of supplies to be purchased with Country funds in each year</th> <th style="text-align: right;"><b>2020</b></th> </tr> </thead> <tbody> <tr> <td>Number of vaccine doses</td> <td style="text-align: right;">561,900</td> </tr> <tr> <td>Number of AD syringes</td> <td style="text-align: right;">-</td> </tr> <tr> <td>Number of re-constitution syringes</td> <td style="text-align: right;">-</td> </tr> <tr> <td>Number of safety boxes</td> <td style="text-align: right;">-</td> </tr> <tr> <td>Value of vaccine doses (US\$)</td> <td style="text-align: right;">368,560</td> </tr> <tr> <td>Total co-financing payments (US\$) (including freight)</td> <td style="text-align: right;">380,500</td> </tr> </tbody> </table>	Type of supplies to be purchased with Country funds in each year	<b>2020</b>	Number of vaccine doses	561,900	Number of AD syringes	-	Number of re-constitution syringes	-	Number of safety boxes	-	Value of vaccine doses (US\$)	368,560	Total co-financing payments (US\$) (including freight)	380,500
Type of supplies to be purchased with Country funds in each year	<b>2020</b>														
Number of vaccine doses	561,900														
Number of AD syringes	-														
Number of re-constitution syringes	-														
Number of safety boxes	-														
Value of vaccine doses (US\$)	368,560														
Total co-financing payments (US\$) (including freight)	380,500														
<b>16. Operational support for campaigns:</b>	<b>Not applicable</b>														
<b>17. Additional Reporting Requirements:</b>	<table border="1"> <thead> <tr> <th></th> <th>Due dates</th> </tr> </thead> <tbody> <tr> <td> <p>To prepare for the annual procurement of vaccines, Country shall submit the following information each year:</p> <ul style="list-style-type: none"> <li>• vaccine stock levels including buffer stock, by end of March;</li> <li>• number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May.</li> <li>• Countries shall report the actual switch date in the first renewal request following the actual implementation.</li> </ul> </td> <td> <p>31 March 2020</p> <p>15 May 2020</p> </td> </tr> <tr> <td>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</td> <td>To be agreed with Gavi Secretariat</td> </tr> </tbody> </table>		Due dates	<p>To prepare for the annual procurement of vaccines, Country shall submit the following information each year:</p> <ul style="list-style-type: none"> <li>• vaccine stock levels including buffer stock, by end of March;</li> <li>• number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May.</li> <li>• Countries shall report the actual switch date in the first renewal request following the actual implementation.</li> </ul>	<p>31 March 2020</p> <p>15 May 2020</p>	In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Gavi Secretariat								
	Due dates														
<p>To prepare for the annual procurement of vaccines, Country shall submit the following information each year:</p> <ul style="list-style-type: none"> <li>• vaccine stock levels including buffer stock, by end of March;</li> <li>• number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May.</li> <li>• Countries shall report the actual switch date in the first renewal request following the actual implementation.</li> </ul>	<p>31 March 2020</p> <p>15 May 2020</p>														
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Gavi Secretariat														

**18. Financial clarifications:**

Not applicable

**19. Other conditions:**

Not applicable

Signed by,

**On behalf of Gavi**



Thabani Maphosa,  
Managing Director, Country Programmes  
30 September 2019